Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OJI-220
- Development stage
- Unknown
- Lead developer
- Oji Pharma
- Administration
- Intravenous
01
Overview
OJI-220 is a wood-derived anticoagulant being developed by Oji Pharma, a subsidiary of Oji Holdings, for the prevention of blood coagulation during extracorporeal circulation in hemodialysis. Derived from forest resources, OJI-220 is intended as a sustainable and culturally inclusive alternative to traditional porcine-derived heparin, addressing supply chain vulnerabilities and religious or cultural restrictions associated with animal-derived products. In March 2026, Oji Pharma submitted a clinical trial plan notification to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to initiate a Phase I first-in-human study. This trial aims to evaluate the safety, tolerability, and pharmacokinetics of OJI-220 in healthy adult males.
Beyond the preview
Go deeper on OJI-220.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OJI-220.